Meriden-based Protein Sciences Corp.said today that a Mexican manufacturer that is licensed to sell its eggless flu vaccine has obtained regulatory approval to begin selling Flublok in Mexico to adults 18 and older.
Flublok will become the first recombinant influenza vaccine to be available in Mexico, Protein Sciences said in a news release.
Manon Cox, president and CEO of Protein Sciences, said recombinant technology is the only technology that can produce an influenza vaccine with the precision to exactly match circulating flu strains.
Other influenza vaccines are made using egg-based technology that is subject to mutations. The Mexican authorities also approved a one-year shelf life and the use of the Flublok trade name.
Mexican pharma company Laboratorios Liomont S.A. de C.V. is the Flublok licensee.
